EMPULSE Response Predictor (Empagliflozin in Heart Failure)
Patient profile
Enter baseline clinical characteristics to calculate the original exploratory index.
Clinical context
EMPULSE was a randomized, double-blind trial of empagliflozin 10 mg once daily versus placebo in 530 patients hospitalized with acute de novo or decompensated chronic heart failure. Treatment was started after clinical stabilization (median 3 days after admission), with follow-up to 90 days.
The primary endpoint was a hierarchical clinical-benefit composite comprising all-cause death, heart-failure events and change in Kansas City Cardiomyopathy Questionnaire Total Symptom Score. The trial reported a stratified win ratio of 1.36 (95% CI 1.09–1.68; P=0.0054) favoring empagliflozin.
What this tool does—and does not do
- Applies the original uploaded code's heuristic point assignments to the entered values.
- Displays its derived index only as an exploratory arithmetic output.
- Does not reproduce the trial's win-ratio analysis or estimate a validated patient-level treatment effect.
- Does not replace assessment of clinical stability, contraindications, renal function, volume status, or clinician judgment.
Clinical evidence
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.